Article
Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6…
Drug Design, Development and Therapy · 2020 · Ortner M, Stange M, Schneider H, Schröder C, Buerger K, Müller C, Müller-Sarnowski F, Diehl-Schmid J, Förstl H, Grimmer T, Steimer W
Key facts
| Title | Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil |
|---|---|
| First author | Ortner M, Stange M, Schneider H, Schröder C, Buerger K, Müller C, Müller-Sarnowski F, Diehl-Schmid J, Förstl H, Grimmer T, Steimer W |
| Journal | Drug Design, Development and Therapy |
| Published | Aug 11, 2020 |
| DOI | 10.2147/DDDT.S247259 |
| Devices mentioned | K090810, K092051, K093114, K100144, K101742, K101744, K101745, K101746, K101752, K101753, K101754, K103656 and 8 more |
| Product codes mentioned | DIF, DIO, DJG, DKB, DKZ, DLZ, GKZ, JJY, KLT, LAF, LCM, LDJ and 2 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1